Distinct MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations
Overview
Authors
Affiliations
MicroRNAs (miRNAs) are postulated to be important regulators in cancers. Here, we report a genome-wide miRNA expression analysis in 52 acute myeloid leukemia (AML) samples with common translocations, including t(8;21)/AML1(RUNX1)-ETO(RUNX1T1), inv(16)/CBFB-MYH11, t(15;17)/PML-RARA, and MLL rearrangements. Distinct miRNA expression patterns were observed for t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) and inv(16) samples. Expression signatures of a minimum of two (i.e., miR-126/126*), three (i.e., miR-224, miR-368, and miR-382), and seven (miR-17-5p and miR-20a, plus the aforementioned five) miRNAs could accurately discriminate CBF, t(15;17), and MLL-rearrangement AMLs, respectively, from each other. We further showed that the elevated expression of miR-126/126* in CBF AMLs was associated with promoter demethylation but not with amplification or mutation of the genomic locus. Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells and enhanced the colony-forming ability of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with AML1-ETO, likely through targeting Polo-like kinase 2 (PLK2), a tumor suppressor. Our results demonstrate that specific alterations in miRNA expression distinguish AMLs with common translocations and imply that the deregulation of specific miRNAs may play a role in the development of leukemia with these associated genetic rearrangements.
Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review).
Li J, Wang Y, Dong C, Luo L Int J Oncol. 2024; 65(6).
PMID: 39364739 PMC: 11542963. DOI: 10.3892/ijo.2024.5700.
Kang K, Gim J, Hong S, Kim H, Choi Y, Park J PLoS One. 2024; 19(8):e0306962.
PMID: 39178208 PMC: 11343415. DOI: 10.1371/journal.pone.0306962.
Sadlocha M, Toczek J, Major K, Staniczek J, Stojko R Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065678 PMC: 11280110. DOI: 10.3390/ph17070827.
Methylation Status of miR-34a and miR-126 in Non-Small Cell Lung Cancer (NSCLC) Tumor Tissues.
Mehrzad N, Zamani M, Rahimi A, Shamaei M, Karimipoor M Iran Biomed J. 2024; 28(1):53-8.
PMID: 38445462 PMC: 10994634. DOI: 10.61186/ibj.3845.
Wang W, Wu X, Zheng J, Yin R, Li Y, Wu X Front Immunol. 2024; 14:1315453.
PMID: 38292478 PMC: 10824954. DOI: 10.3389/fimmu.2023.1315453.